Literature DB >> 32931482

Drugs of unproven benefit for COVID-19: a pharma perspective on ethical allocation of available therapies.

Arthur L Caplan1,2, Joanne Waldstreicher3, Karla Childers3, Aran Maree4.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32931482      PMCID: PMC7598031          DOI: 10.1172/JCI144186

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  8 in total

1.  Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.

Authors:  Jason D Goldman; David C B Lye; David S Hui; Kristen M Marks; Raffaele Bruno; Rocio Montejano; Christoph D Spinner; Massimo Galli; Mi-Young Ahn; Ronald G Nahass; Yao-Shen Chen; Devi SenGupta; Robert H Hyland; Anu O Osinusi; Huyen Cao; Christiana Blair; Xuelian Wei; Anuj Gaggar; Diana M Brainard; William J Towner; Jose Muñoz; Kathleen M Mullane; Francisco M Marty; Karen T Tashima; George Diaz; Aruna Subramanian
Journal:  N Engl J Med       Date:  2020-05-27       Impact factor: 91.245

2.  Lack of antiviral activity of darunavir against SARS-CoV-2.

Authors:  Sandra De Meyer; Denisa Bojkova; Jindrich Cinatl; Ellen Van Damme; Christophe Buyck; Marnix Van Loock; Brian Woodfall; Sandra Ciesek
Journal:  Int J Infect Dis       Date:  2020-05-29       Impact factor: 3.623

3.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

Authors:  Yeming Wang; Dingyu Zhang; Guanhua Du; Ronghui Du; Jianping Zhao; Yang Jin; Shouzhi Fu; Ling Gao; Zhenshun Cheng; Qiaofa Lu; Yi Hu; Guangwei Luo; Ke Wang; Yang Lu; Huadong Li; Shuzhen Wang; Shunan Ruan; Chengqing Yang; Chunlin Mei; Yi Wang; Dan Ding; Feng Wu; Xin Tang; Xianzhi Ye; Yingchun Ye; Bing Liu; Jie Yang; Wen Yin; Aili Wang; Guohui Fan; Fei Zhou; Zhibo Liu; Xiaoying Gu; Jiuyang Xu; Lianhan Shang; Yi Zhang; Lianjun Cao; Tingting Guo; Yan Wan; Hong Qin; Yushen Jiang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Bin Cao; Chen Wang
Journal:  Lancet       Date:  2020-04-29       Impact factor: 79.321

4.  Remdesivir for the Treatment of Covid-19 - Final Report.

Authors:  John H Beigel; Kay M Tomashek; Lori E Dodd; Aneesh K Mehta; Barry S Zingman; Andre C Kalil; Elizabeth Hohmann; Helen Y Chu; Annie Luetkemeyer; Susan Kline; Diego Lopez de Castilla; Robert W Finberg; Kerry Dierberg; Victor Tapson; Lanny Hsieh; Thomas F Patterson; Roger Paredes; Daniel A Sweeney; William R Short; Giota Touloumi; David Chien Lye; Norio Ohmagari; Myoung-Don Oh; Guillermo M Ruiz-Palacios; Thomas Benfield; Gerd Fätkenheuer; Mark G Kortepeter; Robert L Atmar; C Buddy Creech; Jens Lundgren; Abdel G Babiker; Sarah Pett; James D Neaton; Timothy H Burgess; Tyler Bonnett; Michelle Green; Mat Makowski; Anu Osinusi; Seema Nayak; H Clifford Lane
Journal:  N Engl J Med       Date:  2020-10-08       Impact factor: 91.245

Review 5.  Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?

Authors:  Sebastián Ibáñez; Oriela Martínez; Francisca Valenzuela; Francisco Silva; Omar Valenzuela
Journal:  Clin Rheumatol       Date:  2020-06-03       Impact factor: 2.980

6.  Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.

Authors:  Marc Feldmann; Ravinder N Maini; James N Woody; Stephen T Holgate; Gregory Winter; Matthew Rowland; Duncan Richards; Tracy Hussell
Journal:  Lancet       Date:  2020-04-09       Impact factor: 79.321

7.  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

Authors:  Bin Cao; Yeming Wang; Danning Wen; Wen Liu; Jingli Wang; Guohui Fan; Lianguo Ruan; Bin Song; Yanping Cai; Ming Wei; Xingwang Li; Jiaan Xia; Nanshan Chen; Jie Xiang; Ting Yu; Tao Bai; Xuelei Xie; Li Zhang; Caihong Li; Ye Yuan; Hua Chen; Huadong Li; Hanping Huang; Shengjing Tu; Fengyun Gong; Ying Liu; Yuan Wei; Chongya Dong; Fei Zhou; Xiaoying Gu; Jiuyang Xu; Zhibo Liu; Yi Zhang; Hui Li; Lianhan Shang; Ke Wang; Kunxia Li; Xia Zhou; Xuan Dong; Zhaohui Qu; Sixia Lu; Xujuan Hu; Shunan Ruan; Shanshan Luo; Jing Wu; Lu Peng; Fang Cheng; Lihong Pan; Jun Zou; Chunmin Jia; Juan Wang; Xia Liu; Shuzhen Wang; Xudong Wu; Qin Ge; Jing He; Haiyan Zhan; Fang Qiu; Li Guo; Chaolin Huang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Dingyu Zhang; Chen Wang
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

8.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.